Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Andersen, Mads Hald ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER IMMUNOTHERAPY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES; T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN OXYGENASE;

EID: 84942258591     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv154     Document Type: Review

References (63)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C. Regulating the suppressors: apoptosis and infammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother. 2012;61(8):1319-1325.
3. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia. 2008;22(1):49-58.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;19(8):711-723.
5. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366(26):2455-2465.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012;366(26):2443-2453.
7. Kumar V, Sercarz EE. The involvement of T cell receptor peptide-specifc regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med. 1993;178(3):909-916.
8. Broeren C P, Lucassen MA, van Stipdonk MJ, et al. CDR1 T cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions. Proc Natl Acad Sci USA. 1994;91(13):5997-6001.
9. Sorensen RB, Berge-Hansen L, Junker N, et al. The immune system strikes back: cellular immune responses against indoleamine 2, 3-dioxygenase. PLoS One. 2009;4(9):e6910.
10. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, thor Straten P, Andersen MH. Indoleamine 2, 3-dioxygenase specifc, cytotoxic T cells as immune regulators. Blood. 2011;117(7):2200-2210.
11. Sorensen RB, Kollgaard T, Andersen RS, et al. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2, 3-dioxygenase-2. Cancer Res. 2011;71(6):2038-2044.
12. Munir S, Larsen SK, Iversen TZ, et al. Natural CD4(+) T-Cell Responses against Indoleamine 2, 3-Dioxygenase. PLoS One. 2012;7(4):e34568.
13. Andersen MH. The specifc targeting of immune regulation: T cell responses against Indoleamine 2, 3-dioxygenase. Cancer Immunol Immunother. 2012;61(8):1289-1297.
14. Andersen MH. CD4 responses against IDO. Oncoimmunology. 2012;1(7):1211-1212.
15. Straten PT, Andersen MH. Possible benefts of the targeting of indoleamine 2, 3-dioxygenase (IDO) in hepatitis B vaccination. Vaccine. 2011;29(21):3728.
16. Hjortso MC, Larsen SK, Kongsted P, et al. Tryptophan 2, 3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology. 2015;4(1):e968480.
17. Munir S, Andersen GH, Met O, et al. HLA-restricted cytotoxic T cells that are specifc for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013;73(6):1674-1776.
18. Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specifc target for naturally occurring CD4+ T cells. Onco-immunology. 2013;2(4):e23991.
19. Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specifc, cytotoxic T cells. Leukemia. 2013;27(11):2251-2253.
20. Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specifc cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia. 2014;28(1):236-238.
21. Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specifc cyto-toxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J. 2014;4:e230.
22. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identifcation of heme oxygenase-1-specifc regulatory CD8+ T cells in cancer patients. J Clin Invest. 2009;119(8):2245-2256.
23. Larsen SK, Munir S, Woetmann A, et al. Functional characterization of Foxp3-specifc spontaneous immune responses. Leukemia. 2013;27(12):2332-2340.
24. Andersen MH. FOXP3-specifc immunity. Oncoimmunology. 2013;2(10):e26247.
25. Larsen SK, Ahmad SM, Idorn M, et al. Spontaneous presence of FoxO3-spe-cifc T cells in cancer patients. Oncoimmunology. 2014;3(8).
26. Nemazee D. Receptor selection in B and T lymphocytes. Annu Rev Immunol. 2000;18:19-51.
27. Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T cells in the thymus. Annu Rev Immunol. 2012;30:95-114.
28. Cicinnati VR, Zhang X, Yu Z, et al. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int J Cancer. 2006;119(12):2851-2860.
29. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA. 2009;106(33):14010-14015.
30. Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to car-cinoembryonic antigen: ignorance and regulation. Clin Cancer Res. 2007;13(15 Pt 1):4528-4537.
31. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-1154.
32. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2, 3-dioxygenase. J Am Chem Soc. 2007;19(50):15690-15701.
33. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates pro-liferative arrest and anergy induction in response to indoleamine 2, 3-dioxy-genase. Immunity. 2005;22(5):633-642.
34. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27(28):3889-3900.
35. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9(10):1269-1274.
36. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
37. Andersen MH. The targeting of immunosuppressive mechanisms in hema-tological malignancies. Leukemia. 2014; In press.
38. Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T cell leukemia virus type 1 carriers and adult T cell leukemia/lymphoma patients. Leukemia. 2009;23(2):375-382.
39. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101(49):17174-17179.
40. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360-3365.
41. Nomi T, Sho M, Akahori T, et al. Clinical signifcance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151-2157.
42. Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A. Regulatory T cells and immunodefciency in mycosis fungoides and Sezary syndrome. Leukemia. 2012;26(3):424-432.
43. Kollgaard T, Petersen SL, Hadrup SR, et al. Evidence for involvement of clon-ally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia. 2005;19(12):2273-2280.
44. Ame-Thomas P, Le PJ, Yssel H, et al. Characterization of intratumoral follicu-lar helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia. 2012;26(5):1053-1063.
45. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199-213.
46. Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27(2):464-472.
47. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood. 2013;121(5):734-744.
48. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111(3):363-370.
49. Sakaguchi S. Regulatory T cells. Springer Semin Immunopathol. 2006;28(1):1-2.
50. Nair S, Aldrich AJ, McDonnell E, et al. Immunologic targeting of FOXP3 in infammatory breast cancer cells. PLoS One. 2013;8(1):e53150.
51. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007;67(1):371-380.
52. Hurwitz AA, Watkins SK. Immune suppression in the tumor microenviron-ment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother. 2012;61(2):289-293.
53. Zhu Z, Singh V, Watkins SK, et al. High-avidity T cells are preferentially toler-ized in the tumor microenvironment. Cancer Res. 2013;73(2):595-604.
54. Watkins SK, Zhu Z, Riboldi E, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest. 2011;121(4):1361-1372.
55. Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology. 2012;1(2):252-254.
56. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061.
57. Chang X, Gao JX, Jiang Q, et al. The Scurfy mutation of FoxP3 in the thy-mus stroma leads to defective thymopoiesis. J Exp Med. 2005;202(8):1141-1151.
58. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryp-tophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002;196(4):459-468.
59. Xu H, Oriss TB, Fei M, et al. Indoleamine 2, 3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic infammation. Proc Natl Acad Sci USA. 2008;105(18):6690-6695.
60. Iversen TZ, Engell-Noerregaard L, Ellebaek E, et al. Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2, 3 Dioxygenase. Clin Cancer Res. 2014;20(1):221-232.
61. Nagata Y, Hanagiri T, Mizukami M, et al. Clinical signifcance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer. 2009;65(1):91-97.
62. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169(4):1984-1992.
63. Lim ST, Levine AM. Non-AIDS-Defning Cancers and HIV Infection. Curr Infect Dis Rep. 2005;7(3):227-234.